Servier adds mAb platform via takeout of former European biotech darling Symphogen

What was once a high-profile European biotech is now going out quietly as Servier is acquiring Danish mAb company Symphogen A/S for an undisclosed sum.

The two companies are partnered across three clinical stage immuno-oncology programs, a deal the French specialty pharma inherited when

Read the full 437 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE